Erythropoietin Stimulates Tumor Growth via EphB4 by Pradeep, Sunila et al.
Erythropoietin Stimulates Tumor Growth via EphB4
Sunila Pradeep1,*, Jie Huang1,*, Edna M. Mora2,3,4,*, Alpa M. Nick1, Min Soon Cho5, Sherry 
Y. Wu1, Kyunghee Noh1, Chad V. Pecot6, Rajesha Rupaimoole1, Martin A. Stein7, Stephan 
Brock7, Yunfei Wen1, Chiyi Xiong8, Kshipra Gharpure1, Jean M. Hansen1, Archana S. 
Nagaraja1, Rebecca A. Previs1, Pablo Vivas-Mejia2, Hee Dong Han1,9, Wei Hu1, Lingegowda 
S. Mangala1,9, Behrouz Zand1, Loren J. Stagg10, John E. Ladbury10, Bulent Ozpolat11, S. 
Neslihan Alpay11, Masato Nishimura1, Rebecca L. Stone1, Koji Matsuo1, Guillermo N. 
Armaiz-Peña1, Heather J. Dalton1, Christopher Danes1, Blake Goodman1, Cristian 
Rodriguez-Aguayo11, Carola Kruger12, Armin Schneider12, Shyon Haghpeykar1, 
Padmavathi Jaladurgam1, Mien-Chie Hung13, Robert L. Coleman1, Jinsong Liu14, Chun 
Li10, Diana Urbauer15, Gabriel Lopez-Berestein9,11, David B. Jackson7, and Anil K. 
Sood1,9,16
1Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, 
Houston, TX 77584
2Department of Surgery, School of Medicine, University of Puerto Rico, San Juan, Puerto Rico
3University of Puerto Rico Comprehensive Cancer Center, San Juan, Puerto Rico
4Department of Surgical Oncology, Chapel Hill, NC
5Department of Benign Hematology, Chapel Hill, NC
6Division of Hematology/Oncology, Chapel Hill, NC
7MolecularHealth GmbH, Heidelberg, Germany
8Department of Experimental Diagnostic Imaging, The University of Texas MD Anderson Cancer 
Center 77030, USA
9Center for RNA Interference and Non-coding RNA, The University of Texas MD Anderson 
Cancer Center 77030, USA
10Department of Biochemistry and Molecular Biology and Center for Biomolecular Structure and 
Function, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030
11Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer 
Center, Houston, Texas 77030
Correspondence: Anil K. Sood, M.D., Departments of Gynecologic Oncology and Cancer Biology, U.T. M. D. Anderson Cancer 
Center, 1155 Herman Pressler, Unit 1362, P.O. Box 301439 Houston, TX 77030-1439 713-745-5266 (phone), 713-792-7586 (fax), 
asood@mdanderson.org.
*These authors contributed equally to this manuscript.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our 
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of 
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be 
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
SUPPLEMENTAL INFORMATION
Supplemental information includes Extended Procedures, supplementary figures and tables.
HHS Public Access
Author manuscript
Cancer Cell. Author manuscript; available in PMC 2016 November 09.
Published in final edited form as:














13Molecular & Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, 
Texas 77030, USA
14Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, 
Texas 77030, USA
15Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, 
USA
16Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, 
USA
SUMMARY
While recombinant human erythropoietin (rhEpo) has been widely used to treat anemia in cancer 
patients, concerns about its adverse effects on patient survival have emerged. A lack of correlation 
between expression of the canonical EpoR and rhEpo’s effects on cancer cells prompted us to 
consider the existence of an alternative Epo receptor. Here, we identified EphB4 as an Epo 
receptor that triggers downstream signaling via STAT3 and promotes rhEpo induced tumor 
growth and progression. In human ovarian and breast cancer samples, expression of EphB4 rather 
than the canonical EpoR correlated with decreased disease-specific survival in rhEpo-treated 
patients. These results identify EphB4 as a critical mediator of erythropoietin-induced tumor 
progression and further provide clinically significant dimension to the biology of erythropoietin.
INTRODUCTION
Erythropoiesis-stimulating agents (ESAs) such as recombinant human epoetin (rhEpo) and 
darbepoetin are recombinant glycosylated analogues of erythropoietin (Epo) that have been 
used to relieve chemotherapy-induced anemia in cancer patients (Glaspy, 2009a; Sytkowski, 
2007). Epo is a pleiotropic cytokine that regulates erythropoiesis, angiogenesis, 
cytoprotection, and proliferation (Foley, 2008; Glaspy, 2009b). Alarmingly, a growing 
number of studies have demonstrated that ESA-based treatment can compromise overall 
survival of cancer patients (Crouch and DeSantis, 2009; Kumar et al., 2012; Tovari et al., 
2008; Wang et al., 2011), raising the possibility of growth-stimulatory effects on cancer 
cells via the canonical Epo receptor (EpoR) (Aapro et al., 2012; Chateauvieux et al., 2011; 
Hedley et al., 2011; McKinney and Arcasoy, 2011; Rathod and Salahudeen, 2011). 
However, EpoR expression on cancer cells has largely failed to explain the effects of rhEpo 
on tumor growth. For example, rhEpo can affect proliferative and survival responses in 
cancer cells without EpoR expression (Okazaki et al., 2008), while failing to induce 
proliferation in EpoR-positive tumor cells (Belda-Iniesta et al., 2007). Other explanations 
(e.g., EpoR variants) have also been inadequate in explaining the effects of rhEpo on tumor 
growth (Foley, 2008).
Evidence from other therapeutic areas has also suggested the existence of an alternative Epo 
receptor. For example, carbamylated Epo (cEpo) does not stimulate erythropoiesis, yet 
prevents tissue injury in response to hypoxic conditions (Chen et al., 2009; Leist et al., 2004; 
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Zamora et al., 2005) in an EpoR independent manner (Leist et al., 2004). Such observations, 
combined with lack of a convincing molecular explanation underlying the effects of rhEpo 
on cancer growth prompted us to consider the existence of an alternative Epo receptor. 
Using a hypothesis-driven in silico strategy, we further explored ephrin-type B receptor 4 
(EphB4) as an alternative candidate Epo receptor that accounts for many of the growth-
stimulatory effects of rhEpo in tumors.
RESULTS
In silico identification of an alternative candidate Epo receptor
Epo-mediated tissue protection under conditions such as hypoxia occurs in an EpoR 
independent manner (Brines and Cerami, 2012; Brines et al., 2008). We reasoned that while 
expression of an alternative Epo receptor may mediate potential therapeutic responses to 
Epo under low-oxygen conditions (e.g., after ischemic stroke), expression of this same 
receptor on tumor cells could provide them with a survival advantage in response to Epo 
treatment. Such an “off-target” mechanism could have serious implications for cancer 
patient survival and might explain the emerging clinical evidence supporting such an effect. 
To identify this elusive receptor, we analyzed the membrane-bound portion of the proteome 
for candidate receptors possessing structural, regulatory, and functional features consistent 
with Epo binding, response to hypoxic conditions, and tumorigenic signaling. Employing a 
combination of bioinformatics and text-mining approaches, we identified EphB4, IL6rb, 
Tie1, Tf, and Ghr as potential candidates. While EphB4 and IL6rb showed evidence of 
involvement in angiogenesis and erythropoiesis, analysis of the Epo genomic locus revealed 
that it is contiguous to the EPHB4 gene, a phenomenon not uncommon to many functionally 
interacting proteins (Figure S1A). Subsequent structural analyses identified potential Epo 
binding sites on EphB4, leading us to select this molecule as our prime candidate for an 
alternative Epo receptor (Figure1A).
We initially assessed whether rhEpo binds to EphB4 using fluorescence microscale 
thermophoresis (MST) and surface plasmon resonance (SPR). MST experiments with 
fluorophore labeled rhEpo demonstrated binding to EpoR with an apparent dissociation 
constant (KD,app) of 28.0 ± 14.0 nM (Figure 1B) and EphB4 with a KD,app value of 880.6 ± 
128.6 nM; Figure 1C). EphB4 and EphrinB2 bound with a KD,app value of 140.5 ± 28.3 nM 
(Figure 1D). The BSA control showed no binding to EpoR or EphB4 (Figures S1B and 
S1C). SPR studies revealed that rhEpo competes with EphrinB2 for EphB4 in a dose-
dependent manner (Figures 1E and 1F). Controls showed EphrinB2 binding to EphB4 and 
rhEpo binding to EpoR (Figures S1D and S1E). A ligand with lower binding affinity can 
bind to its corresponding receptor and exert biological functions (Figure S1F). To test the 
specificity of rhEpo binding to EphB4, we also tested several other Eph receptors. No 
binding was noted between rhEpo and EphA2, EphA3 or EphB2 (Figure S1G-S1I); for 
controls, we used EphrinA1 as the ligand for EphA2, EphrinB2 for EphB2, and EphrinA2 
for EphA3. Presence of rhEpo did not interfere with the binding of these ligands to their 
corresponding receptors (Figure S1J-L). Both rhEpo-alpha and rhEpo-beta also bind to 
EphB4 (50 ng/mL) in the presence of [I125] rhEpo (Figures S1M and S1N).
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Next, we examined a panel of cell lines for EpoR, EphB4, and EphrinB2 expression (Figure 
S1O-S1Q). EphrinB2 is present in endothelial cells both in vitro and in vivo, but no 
significant increase in its expression was observed after rhEpo stimulation (Figure S1R-
S1U). The A2780 cells express both EpoR and EphB4, but lack EphrinB2 (Figures S1O-
S1Q) and IL6rb (Figures S1V and S1W). To confirm specificity of the EpoR antibody, we 
ectopically expressed HA tagged EpoR in A2780 cells and detected EpoR expression using 
HA antibody (Figure S1X).
rhEpo binds to EphB4
Next, we established stably transfected clones with shRNA against EpoR (shEpoR), EphB4 
(shEphB4) or both in A2780 cells (Figure S2A-S2D). ShEpoR clone 3 and shEphB4 clone 1 
were used for subsequent experiments. rhEpo competitively inhibited [I125]rhEpo binding to 
A2780-shEpoR and A2780-shEphB4 cells (Figure 2A); there was no binding of [I125]rhEpo 
to A2780-shEpoR/shEphB4 cells (Figure 2B). To further examine the potential for EphB4 
binding to Epo, we also generated EpoR−/− MEFs (EphB4 positive) from EpoR−/− mice and 
found that [I125]rhEpo can bind to these cells (Figure 2C).
To further examine binding between Epo and EpoR or EphB4, we ectopically expressed 
EpoR or EphB4 in EpoR/EphB4-null Cos-1 cells. rhEpo competitively inhibited [I125]rhEpo 
binding to both clones (Figure S2E and Table S2) and no binding was noted in Cos-1-EV 
(empty vector) cells. To test the specificity of shRNA, additional clones were tested with 
similar results obtained (Figure S2F). Similar binding patterns were also noted in MDA-
MB231 (Figure S2G) and MCF-7 breast cancer cells (Figure S2H). Next, we designed 
several peptides from the EphB4 extracellular domain based on potential interaction sites 
from the 3D structures of EphB4:EphrinB2 and EpoR:Epo complexes (Figure S2I;). In 
competitive binding assays with rhEpo and each peptide (Figure 2D; Figure S2J), only the 
EEL peptide (amino acids 43-58 of the EphB4 extracellular domain covers the C-D loop 
(Chrencik et al., 2006a), a region involved in Ephrin-binding) inhibited the binding of [I125]-
rhEpo to A2780-shEpoR cells. Alignment of the N-terminal domains of EphB4 and EpoR 
indicated that the EEL peptide contains several residues that are identical or similar to 
residues in the A-B loop of EpoR, which are involved in Epo binding (Syed et al., 1998). 
We designed specific plasmids encoding EphB4 with a mutation at the EphrinB2 binding 
domain. The mutation site corresponds to the amino acids included in the EEL peptide: 
Ser46, Leu48, Glu50, Glu44 and Tyr58 (Table S1) (Chrencik et al., 2006a; Chrencik et al., 
2006b). The Ser46 mutated site did not affect rhEpo binding, but mutations in Leu48 
blocked rhEpo binding (Figure S2K and Table S2). We also mutated shared residues (Glu50 
or Glu44, Tyr58) involved in Epo binding in both EphB4 and EpoR; mutation on Glu44 or 
Glu50 (but not Tyr 58) interrupted the binding of Epo to EphB4 (Figure S2L and Table S2). 
Using proximity ligation assays, we found that Epo and EphB4 interact directly in Cos-1/
EpoR and Cos-1/EphB4 cells (Figure 2E-2F).
Next, we performed competitive binding studies where A2780-shEpoR cells were exposed 
to soluble EphB4, EphrinB2, or EpoR. Soluble EpoR did not inhibit the interaction between 
rhEpo and EphB4, however, soluble EphB4 and soluble EphrinB2 blocked this interaction 
(Figure 2G). In A2780-shEphB4 cells, soluble EpoR competitively inhibited rhEpo binding 
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to EpoR, but soluble EphB4 and soluble EphrinB2 did not block the interaction between 
rhEpo and EpoR (Figure S2M). To test the specificity of competitive inhibition, we 
performed assays using IL3 [known to form heterodimers with EpoR (Krosl et al., 1996)] 
and CXCL12 (unrelated to EpoR), and no inhibition was noted (Figure S2N).
Epo-mediated EphB4 activation and signaling
Serum rhEpo levels of 1-200 IU/mL in individuals given rhEpo have been reported 
(McMahon et al., 1990; Olsson-Gisleskog et al., 2007), but no data regarding levels in the 
tumor microenvironment were found. Thus, we evaluated human and murine Epo levels in 
A2780 tumors from mice treated with rhEpo (Figure S3A-D). Hemoglobin levels increased 
with rhEpo treatment, but there were no effects on white blood cells or platelet counts 
(Figure S3E). On the basis of these data, we used 1-50 IU/mL rhEpo for subsequent in vitro 
experiments. To test whether rhEpo activates EphB4, we exposed A2780, SKOV3, and 
MDA-MB231 cells to rhEpo. Epo and EphB4 bind to each other in a sustained manner 
(Figure S3F), leading to phosphorylation of EphB4 (Figure 3A; Figure S3G). To address 
whether cross-activation between EpoR and EphB4 could occur upon rhEpo stimulation, we 
immunoprecipitated EpoR and probed for EphB4 in A2780 parental cells, but no direct 
interaction was detected (Figure S3H). EPHB4 mRNA levels showed modest changes in cell 
cycle phases in two out of four cell lines tested. To further confirm this, A2780 and MDA-
MB231 cells were labeled with EphB4 antibody and FACS sorted according to cell cycle. 
Our data show that there were no significant change in EphB4 protein expression during 
different phases of the cell cycle (Figure S3I).
As expected, rhEpo stimulation of A2780-shEphB4 cells, but not A2780-shEpoR cells, 
resulted in activation of the Jak2/STAT5 pathway (Figure 3B). In contrast, rhEpo 
stimulation of A2780-shEpoR, but not A2780-shEphB4 cells, resulted in STAT3 activation 
(Figure 3B and Figure S3J). To further exclude the possible effect of EpoR in these 
experiments, we used EpoR−/− MEFs, which are EphB4 positive (Figure S3K). We 
stimulated the EpoR−/− MEFs with rhEpo and this resulted in increased pSTAT3 and pSrc 
levels (Figure 3C). Similarly, EphrinB2 treatment also resulted in STAT3 and Src 
phosphorylation (Figure S3L). Immunoprecipitation (IP) of EphB4 followed by 
immunoblotting (IB) for STAT3 revealed no evidence of direct binding between these 
proteins (data not shown). We then evaluated Src as a possible mediator between EphB4 and 
STAT3. Src IP followed by EphB4 IB revealed binding of these two proteins in A2780-
shEpoR cells after rhEpo stimulation (Figure 3D). There was no binding between EphB4 
and Jak2. In A2780-shEpoR cells, PP2 (Src inhibitor), but not PP3 (inactive), treatment 
resulted in blockage of rhEpo-induced STAT3 activation (Figure 3E). Similar results were 
noted with Src siRNA (Figure 3E and Figure S3M). To determine whether activated STAT3 
binds to DNA upon exposure to rhEpo, we used a consensus oligonucleotide containing a 
binding site for STAT3. rhEpo treated A2780-shEpoR, but not the -shEphB4 cells, had >3-
fold increase in nuclear STAT3 levels compared to untreated cells (Figure 3F). To further 
document the functionality of cellular EphB4, A2780-shEpoR cells were exposed to 
EphrinB2-Fc, which resulted in EphB4, Crk/Abl, and Akt phosphorylation (Figure S3N). 
We further confirmed this result in the EpoR−/− MEFs (Figure S3O).
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rhEpo induces EphB4-mediated functional effects in vitro
Exposure to rhEpo resulted in a significant increase in proliferation, migration, and invasion 
of the A2780 parental and -shEpoR cells, but not A2780-shEphB4 cells (Figures 4A-C and 
S4A-C). Given the activation of STAT3 signaling in response to rhEpo in A2780-shEpoR 
cells, we examined the effects of STAT3 silencing on these cells (Figure S4D). STAT3 
siRNA blocked Epo-induced proliferation (Figure S4E), migration, and invasion of A2780-
shEpoR cells (Figure 4D). EphrinB2 also increased invasion, migration, and proliferation of 
the A2780 parental and -shEpoR cells, but not the -shEphB4 cells (Figure S4F and S4G); 
these effects were disrupted by STAT3 or Src siRNA (Figure S4H). EphrinB2 levels are not 
increased in response to rhEpo treatment (Figure S4I). Similar effects of rhEpo were noted 
in the MCF7 breast cancer cells using EpoR or EphB4 targeted siRNA (Figure S4J). 
Moreover, rhEpo increased proliferation, migration, and invasion of Cos-1 cells transfected 
with EphB4. These effects did not occur in Cos-1 cells expressing EpoR or mutated EphB4 
(Figures S4K-M).
rhEpo induces EphB4-mediated biological effects in vivo
Significant increases in tumor growth following rhEpo treatment (Figures 5A and S5A) 
were noted in the SKOV3ip1, A2780, and HeyA8 ovarian cancer mouse models. Using 
fluorescently labelled (Alexa Flour 555) rhEpo, we confirmed the accumulation of rhEpo in 
tumors (Figure S5B). rhEpo administration increased the level of EphB4 phosphorylation in 
tumors (Figure S5C). Additional experiments revealed that rhEpo stimulated in vivo growth 
of A2780-shControl and -shEpoR cells, but not -shEphB4 or -shEpoR/shEphB4 cells 
(Figure S5D). Given the limitations of shRNA for therapeutic applications, we also used 
siRNA packaged in DOPC nanoliposomes for systemic siRNA delivery to tumors (Ahmed 
et al., 2010; Halder et al., 2005) (Merritt et al., 2008). rhEpo treatment increased tumor 
growth in the A2780 tumors treated with DOPC alone or control siRNA-DOPC treatment 
groups (Figure S5E). While EpoR siRNA-DOPC had no effect on rhEpo-stimulated tumor 
growth, EphB4 siRNA-DOPC or combined EphB4/EpoR siRNA-DOPC completely 
abrogated rhEpo induced tumor growth (Figure 5B, Figure S5F and S5G). To exclude 
potential off-target effects, we tested three additional EphB4 siRNA sequences. All three 
sequences inhibited rhEpo induced tumor growth in the A2780 model in vivo. (Figure S5H). 
Moreover, Cos-1 cells, which do not express EpoR or EphB4, were transfected with either 
WT EphB4 or a mutated EphB4 plasmid carrying a non-sense mutation at the EphB4 siRNA 
target site. Cells transfected with WT EphB4 exhibited decreased EphB4 expression 
following EphB4 siRNA transfection, whereas cells with mutated EphB4 had no changes in 
EPHB4 expression (Figure S5I). Consistent with in vitro findings, STAT3 siRNA-DOPC 
also blocked rhEpo stimulated growth in the A2780-shEpoR model (Figure S5J). Similar 
effects were noted with the MDA-MB231 (ER-negative; Figure 5C) and MCF-7 (ER-
positive; Figure S5K) breast cancer models. Moreoever, in the RMG2 ovarian cancer model 
(EpoR+/EphB4−), rhEpo had no significant effect on tumor growth (Figure S5L). Next, we 
ectopically expressed WT EphB4 or the mutated form of EphB4 that does not bind to Epo in 
the RMG2 (EphrinB2 negative) cells; while rhEpo stimulated the growth of RMG2-EphB4 
tumors (WT), it had no effect on the RMG2-EphB4 mutated model (Figure 5D and Figure 
S5M). Protein assessment of A2780 tumors harvested at the end of the experiment revealed 
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>90% EpoR or EphB4 gene silencing in the respective groups (Figure S5N). Effects of 
EpoR or EphB4 silencing on downstream signaling were also found to be consistent with the 
aforementioned in vitro findings (Figure S5N).
To determine the effect of rhEpo on cancer cell invasion in vivo, we analyzed H&E sections 
from rhEpo-treated A2780-shEpoR tumors. These results show that rhEpo administration 
led to a more invasive phenotype characterized by infiltration of tumor deeply through the 
muscle layers, while tumors in untreated mice remained encapsulated (Figures S5O and 
S5P).
We next used the SKOV3ip1 (EphrinB2 negative) model to examine potential effects of 
endogenous EphrinB2 on murine cells. For this experiment, we used RGD-labeled chitosan 
(CH) nanoparticles that are highly efficient for targeted siRNA delivery (Han et al., 2008; 
Pradeep et al., 2014; Rupaimoole et al., 2014; Wu et al., 2014). Tumor-bearing animals were 
randomized to: 1) Control siRNA; or 2) human EpoR siRNA (hEpoR siRNA) and mouse 
EphrinB2 siRNA (mEphrinB2 si). rhEpo stimulated tumor growth in both groups (Figure 
S5Q and S5R). To exclude the potential effects of murine EphrinB2 on EphB4 receptor in 
tumor cells, we performed an additional experiment where ID8VEGF (EphrinB2−/EpoR−/
EphB4+) cells were injected i.p. into EphrinB2 KO mice (Figure 5E, Figure S5S and S5T). 
We found that rhEpo still promotes tumor growth in this model.
EphB4 expression correlates with clinical outcome in ESA-treated patients
Next, we addressed potential effects of tumoral EpoR or EphB4 expression on the effects of 
ESA treatment in patients with ovarian (n = 175) or breast (n = 88) cancer (Figure 6A-D and 
Figure S6A-C). EphB4 and EpoR protein levels were significantly correlated with mRNA 
expression levels (Figure S6D and S6E). The mean age of the patients with epithelial 
ovarian cancer was 58.2 years (range, 20-92 years); 85% had serous histology, and 91% had 
high-grade tumors. All patients were primarily treated with combination platinum and 
taxane chemotherapy. EpoR and EphB4 overexpression was detected in 79% and 39% of 
epithelial ovarian cancer samples, respectively (Tables S3). The disease-specific survival 
(DSS) in patients with high EphB4-expressing tumors was significantly shorter than for 
patients with low EphB4-expressing tumors (p<0.001; Figure 6E; Table S4). DSS did not 
differ by level of EpoR expression (Figure 6F; p=0.64; Table S4). In multivariate analysis, 
EphB4, but not EpoR overexpression was an independent predictor of poor survival (Table 
S4). High level of EphB4 expression, but not EpoR, was associated with shorter overall 
patient survival compared to low EphB4 expression (p < 0.001; Figure 6G).
Next, we addressed the potential impact of ESA-based treatment on survival of patients with 
ovarian cancer. ESA-based treatment was associated with shorter survival in patients with 
EphB4-overexpressing tumors (2.18 versus 4.52 years; p=0.0004), but not in patients with 
low EphB4-expressing tumors (4.38 versus 5.28 years; p=0.19; Figure 6H). To determine if 
EphB4 interacts with ESA-based treatment to adversely impact outcomes, a Cox 
proportional hazards model was created (Table S4). In this model, patients with high EphB4 
expression and ESA-treatment had increased risk of disease-specific mortality than those 
with low EphB4 and no ESA-therapy (HR 5.66 (95% CI 3.11-10.31), p<0.0001). In contrast, 
patients with low EphB4 and ESA-therapy did not demonstrate a similar relationship (HR 
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0.88 (95% CI 0.45-1.74), p=0.71). ESA-therapy was associated with worse survival in 
patients with low EpoR expression (p=0.03, Figure S6F). To determine the specificity of the 
ESA and EphB4 interaction, a parallel analysis was performed with IL6rb, one of the other 
candidates identified in the in silico screen; there was no impact on patient survival based on 
IL6rb expression (Figure S6G-S6I).
To determine whether EphB4 expression is predictive of outcome in patients with other 
malignancies, we also tested breast cancer samples (n=88; further details included in Tables 
S5 and S6). DSS of ESA-treated breast cancer patients was significantly lower compared to 
untreated patients (Figure 6I). ESA-treated breast cancer patients with high EphB4 
expression showed significantly lower survival compared to untreated patients (Figure 6J). 
For those with available Her2 and estrogen receptor status, ESA treatment was associated 
with increased risk of death (HR: 4.09; 95% CI=1.32-12.68). After stratifying patients 
according to receptor status, those with Her2 negative tumors had an increased risk of death 
with ESA therapy (HR: 10.3; 95% CI=1.07-98.76; Table S7). Collectively, we propose a 
model whereby Epo interacts with the EphB4 receptor, leading to downstream Src and 
STAT3 activation (Figure 7).
DISCUSSION
This study identified EphB4 as a previously unrecognized Epo receptor that is responsible 
for the deleterious effects of exogenous Epo administration on the survival of cancer 
patients. The computational, biochemical, molecular, cellular, animal, and clinical data 
support the role of EphB4 as a functional Epo receptor.
Administration of exogenous Epo in patients with cancer has been linked with tumor 
progression (Crouch and DeSantis, 2009; Kumar et al., 2012; Tovari et al., 2008; Wang et 
al., 2011), but the mechanism remained elusive until now. Although the interaction between 
Epo and the canonical EpoR can explain tumor progression in some models, mounting 
evidence indicates that this interaction is not involved in most Epo-induced tumor growth 
(Sturm et al., 2010 and Kassem and Yassin, 2010). A possible explanation to this puzzle is 
the concept that alternative EpoRs (e.g. EpoR–IL3 heterodimer and soluble EpoR) can 
account for non-hematological effects, but these alternative receptors have not explained 
Epo-induced tumor progression. Our results have broad implications for understanding Epo 
biology. For example, the Epo-EphB4 pathway could potentially explain some of the non-
hematologic functions of Epo. EphB4 is present, and tends to colocalize with EpoR in a 
subset of cortical neurons (Figure S6J) (Uhlen et al., 2015). Pharmacological doses of cEpo 
have neuroprotective effects that have been shown to be independent of EpoR function 
(Sturm et al., 2010). Epo has been shown to prevent chemotherapy-induced neurotoxicity in 
cancer patients (Kassem and Yassin, 2010). Administration of Epo after a stroke can reduce 
the extent of damage and accelerate patient recovery (Chang et al., 2005; Noguchi et al., 
2007).
EphB4 appears to be a low affinity receptor for rhEpo based on the biochemical data. The 
concentration of rhEpo used for the biological experiments (50 IU/ml) corresponds to 10-15 
nM, which is 1% to 2% of the KD value (KD=881nM) for the binding of rhEpo to EphB4, as 
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measured in the MST assay. These data suggest that as a relatively low-affinity binding 
event, interaction between rhEpo and EphB4 is a pharmacologically efficient process. Other 
ligand-receptor systems that display similar phenomena have been reported previously 
(Authier and Desbuquois, 2008; Hutchinson et al., 2003; Mason and Tager, 1985). Whether 
EphB4 exists as a dimer in cancer cells is not known and will require additional work. Our 
findings can also be extrapolated to the mechanism by which Epo could potentially induce 
neovascularization in normal organs (Davies et al., 2009; Salvucci et al., 2006), a process 
also regulated by EphB4.
The discovery of EphB4 as an alternative Epo receptor has multiple clinical implications 
including opportunities for patient stratification, and anti-EphB4 approaches to abrogate the 
stimulatory effects of Epo on tumor growth. In summary, Epo-EphB4 interactions on tumor 




Female athymic nude mice (NCr-nu) and immunocompetent (C57BL/6) mice (5–8 weeks) 
were purchased from the NCI-Frederick Cancer Research and Development Center 
(Frederick, MD). B6;129S-Eportm1Liz/J and B6.129S7-Efnb2tm2And/J mice were 
purchased from Jackson Laboratory and maintained as previously described (Merritt et al., 
2008b; Thaker et al., 2006). All animal work was performed in accordance with protocols 
approved by the M.D. Anderson Institutional Animal Care and Use Committee. Mice were 
cared for in accordance with guidelines set forth by the American Association for 
Accreditation of Laboratory Animal Care and the US Public Health Service Policy on 
Human Care and Use of Laboratory Animals.
MST experiments were performed using a NanoTemper NT.115 Monolith system (Jerabek-
Willemsen et al., 2011). Temperature was maintained at 25°C for all experiments. Purified, 
recombinant proteins were obtained from Cell Sciences (epoetin) and Sino Biological 
(EpoR, EphB4, and EphrinB2/Fc). Fluorescence labeling of rhEpo and EphB4 was achieved 
through primary amide coupling with NT-647 dye (NanoTemper), and labeled protein was 
purified from free dye using Sephadex G25 resin (GE Healthcare). The concentration of 
NT-647 labeled protein was maintained at 25 nM throughout and titration series of 
unlabeled protein were accomplished with dilution in assay buffer (10 mM HEPES, pH 7.5, 
150 mM NaCl, 0.5 mM TCEP, 0.05% Tween-20). Individual samples were made up to ≤5 μl 
in standard, glass capillaries (NanoTemper). A thermal gradient of ~3°C produced the 
characteristic thermophoretic trace for each sample. Each data point represents the average 
of triplicate repeats, and reported error is the standard deviation of triplicate repeats. Data 
were analyzed using NanoTemper software. Affinities calculated near the concentration of 
labeled protein (25 nM) are denoted KD,app as a higher inherent error is expected.
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Surface plasmon resonance (SPR): Immobilization of EphB4 receptor to sensor chip
The stock solution (100 μg/mL) of EphB4 in phosphate-buffered saline (PBS) was diluted to 
25 μg/mL with 10 mM sodium acetate buffer at pH 4.5 and immobilized to a CM5 sensor 
chip using the amine coupling reaction following manufacturer-provided procedures 
(BIACORE). Briefly, the surfaces of the chips in flow cells (FC)-1, -2 were activated by 
exposing them to a mixture of 200 mM N-ethyl-N’-dimethylaminopropyl carbodiimide and 
50 mM N-hydroxysuccinimide for 7 min. FC-1 was used as a reference surface and was 
directly deactivated by injecting 1 M ethanolamine at pH 8.5 for 7 min. FC-2 was injected 
with 25 μg/mL EphB4, followed by injection of 1 M ethanolamine to block the remaining 
activated ester groups on the surface. The chip was allowed to stabilize for at least 2 h in 
HBSEP running buffer before injecting test analytes. The experiments were performed in 
triplicate.
SPR Binding assays between EphrinB2 and EphB4
Binding assays were performed in triplicate at 25 °C in HBSEP running buffer. EphrinB2 
was diluted in HBSEP buffer, filtered, degassed, and injected at concentrations between 0.6 
nM and 40 nM at a flow rate of 30 μl/min. The injection time of EphrinB2 into the HBSEP 
buffer was 7 min, followed by a 3-min dissociation period. The chips were regenerated 
using a 30 s pulse of 10 mM glycine (pH 2.2) after each binding circle. Each cycle consisted 
of a 2-min waiting period to allow monitoring of the baseline binding stability. For 
subtraction of bulk effects, caused by changes in the buffer composition or nonspecific 
binding, we performed double-referencing. Therefore, all analyzed samples were 
additionally injected onto an uncoated reference surface, including a sample of the running 
buffer, which was also tested on the EphB4 coated flow cell.
Competition of rhEpo and EphrinB2 for EphB4 receptor
The ability of rhEpo to inhibit EphrinB2 binding to EphB4 was assessed in a competitive 
binding assay. Serial dilutions of rhEpo from 0.39 to 100 nM were mixed with a 
predetermined concentration of EphrinB2 (2.5 nM) in HBSEP buffer containing 0.1 mg/mL 
BSA to prevent nonspecific binding. The mixture was injected at a flow rate of 30 μl/min 
over an EphB4-coated flow cell as well as over a control flow cell. After each injection, the 
signal from the control flow cell was subtracted, and then the relative amount of protein 
bound to EphB4 was recorded as the net response over pre-injection baseline. Regeneration 
was achieved with a 30 s pulse of 10 mM glycine (pH 2.2). Bound protein shown as 
response units (RU) was plotted as a function of Epo concentration and fit to a three-
parameter non-linear regression using Graphpad Prism 5.0.
The ability of rhEpo binding to other Eph receptors was tested by competitive binding assay. 
To test this, tubes were coated with 100 μL of EphA2 (100 nM), EphA3 (100 nM) and 
EphB2 (100 nM) at 4°C. Serial dilutions of Ephr inA1, EphrinA2 and EphrinB2 from 0.01 
to 100 nM were mixed with a predetermined concentration of [I125] rhEpo (10 nM) in 
HBSEP buffer containing 0.1 mg/mL BSA to prevent nonspecific binding. Radioactivity 
(signal) was measured after 2 hr of incubation. The data are expressed as % of binding. The 
experiments were performed in triplicates.
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Immobilization of monoclonal mouse anti-human IgG (Fc) antibody to sensor chip and 
analysis of binding between Epo and rhEpoR-Fc
The same procedure as described before was performed to coat the monoclonal mouse anti-
human IgG (Fc) antibody (Biacore, BR-1008-39) on CM5 chip which is ready for capture 
analysis. In capture analysis, each cycle consisted of (i) capture of rhEpoR-Fc by injection 
of 500 μL rhEpoR-Fc over flow cell 2, (ii) 1 min stabilization time, (iii) 60 μL injection of 
Epo (concentration range of 13.4 nM to 107 nM in 2-fold dilution increments) over flow 
cells 1 and 2 with flow cell 1 as the reference flow cell, (iv) 5 min dissociation (buffer flow), 
(v) regeneration of anti-human IgG surface with a 120 s injection of 3M MgCl2 at 50 μL/
min, (vi) 1 min stabilization time before start of next cycle. Signal was monitored as flow 
cell 2 minus flow cell 1. All samples and a buffer blank were injected in duplicate.
Clinical Samples
After informed consent, data and paraffin-embedded tissue samples on 175 consecutive 
patients with ovarian cancer and 88 consecutive patients with breast cancer were collected 
according to M.D. Anderson Institutional Review Board-approved protocol. There were no 
significant differences in patient demographics, clinical stage, or known prognostic factors 
for either cohort of patients. All patients in the ovarian cancer cohort were treated with a 
combination of surgical cytoreduction followed by adjuvant taxane and platinum 
chemotherapy. Clinical samples were scored for staining with the EphB4, EpoR, and IL-6rb 
antibodies by a board-certified pathologist who was blinded to the clinical outcome of the 
patients. EphB4, EpoR and IL-6rb expression was determined semi-quantitatively by 
assessing the distribution of the positive cells and the staining intensity in the tumor cells, as 
previously described (Lu et al., 2010; Merritt et al., 2008a). An overall H-score >100 was 
defined as high expression and ≤100, low expression, according to the method described by 
McCarty et al. which considers both the intensity of staining and the percentage of cells 
stained. The expression of EpoR and EphB4 was also verified by qRT-PCR in selected 
patients. To test for a difference in survival by EphB4 expression, we used 175 patients with 
60% in the first group (low expression) and specified median survival time of 6.7 years in 
low expressers and 3 years in high expressers of EphB4. We thereby expected 65 deaths 
among low expressers and 42 deaths among high expressers and consequently had 99% 
power to detect the observed difference in survival curves. A similar post-hoc power 
analysis was performed in the breath cohort and we had 70% power to detect the observed 
difference in survival curves.
Statistical analysis
Fisher exact test was used to examine associations between EphB4, EpoR and IL6rb 
expression and ESA treatment in human samples and clinical variables. Kaplan-Meier 
survival curves and log-rank tests were used to examine the association between tumor 
expression of EphB4, EpoR or IL6rb and patient disease-specific survival with and without 
ESA treatment. Multivariable analysis was performed using the Cox proportional hazards 
model. The data for this analysis were tested (plot of differences in log of cumulative hazard 
rates of test variable against time) and found to confirm to the proportional hazards 
assumptions. For animal experiments, 10 mice were assigned to each treatment group. This 
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sample size gave 80% power to detect a 50% reduction in tumor weight with 95% 
confidence. Mouse and tumor weights and the number of tumor nodules in each group were 
compared. Data are presented as mean ± S.D. Statistical comparisons between experimental 
groups were analyzed by unpaired Student’s t test, and a two-tailed p < 0.05 was taken to 
indicate statistical significance. For analyzing the correlation, we used Pearson’s test and the 
p values are indicated. We also used Mann-Whitney rank sum test as indicated. All 
statistical tests were two-sided. For in vitro studies, those with continuous variables were 
compared using the student t-test if normally distributed. Differences in variables that were 
not normally distributed were compared using a nonparametric test (Mann-Whitney U test). 
Again, a p value less than 0.05 was deemed statistically significant. All statistical tests were 
two-sided. Only two-tailed values are reported in this study.
Full Methods are described in the supplemental information.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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• EphB4 functions as a canonical Epo receptor
• rhEpo-mediated EphB4 activation triggers downstream signaling via STAT3
• rhEpo induces EphB4-mediated functional and biological effects
• EphB4 expression negatively correlates with clinical outcome
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The mechanisms underlying the adverse effects of Epo stimulating agents on reduced 
survival of cancer patients are not well understood. Herein, we identified EphB4 as an 
alternative Epo receptor, which triggers Src/Stat3 signaling via EphB4. We also showed 
that rhEpo-mediated tumor growth can be abrogated by targeting EphB4 in vivo. In our 
study, evaluation of human ovarian and breast cancer samples revealed that EphB4, but 
not the canonical EpoR, correlated with clinical outcome in Epo-treated patients. Overall, 
we present converging evidence from in vitro, in vivo, and clinical studies that EphB4 is 
a critical mediator of Epo-induced cancer growth. Our study provides an important and 
clinically significant dimension to the biology of erythropoietin.
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Figure 1. Epo Binds to EphB4
(A) X-ray crystal structure of EphB4 (green), EphrinB2 (blue) and Epo (blue) -EpoR (green) 
complex. The C-D region from which the inhibitory peptide has been derived from is 
highlighted in red. E43, E44 and L45 are involved in EphrinB2 binding. Interactions 
between homology region with EpoR and ligand are shown in detail: E43, E44 and L45 of 
EphB4 interact with K60, T114 and K116 of EphrinB2. The acidic residues in the apical 
position of the loop (E50, E51) are shown as well. The A-B loop region homologous to the 
inhibitory peptide is highlighted in red. Interaction between K97 and R14 of Epo with acidic 
residue located on the apical loop of the homology region (E34). The region homologous to 
EphB4 ranges from E24, E25, L26 to F39. E24, E25 and L26 of EpoR are homologous to 
residues E43, E44 and L45 of EphB4 which are involved in Ephrin ligand binding. Acidic 
residues are located in the loop in an apical position similar to the location of acidic residues 
in the A-B loop region of Epo Receptor. (B) Fluorescence microscale thermophoresis 
analysis of Epo binding to EpoR or (C) EphB4. (D) EphrinB2 binding to labeled EphB4. (E) 
Surface competition assay (SCA) of Epo and EphrinB2 with coated EphB4 receptor using 
the BIAcore instrument for detection of bound protein. Serial dilutions of Epo were mixed 
with EphrinB2 and injected onto a CM5 chip to which EphB4 was bound. (F) Bound protein 
shown as response units (RU) at the end of association was plotted as a function of Epo 
concentration and fit with a three-parameter non-linear regression using Graphpad Prism 
5.0. Samples and a buffer blank were injected in duplicate. Mean ± SEM values are shown. 
(n=3). (See also Figure S1).
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Figure 2. Characterization of rhEpo binding to EphB4 cells
(A) Analysis of competitive binding of [I125]rhEpo to A2780-parental, -shEpoR, -shEphB4, 
and shEpoR/shEphB4 cells. (B) Kinetics of [I125]rhEpo binding to A2780-parental, -
shEpoR, -shEphB4, and -shEpoR/shEphB4 cells. (C) Analysis of competitive binding of 
[I125]rhEpo to EpoR WT and EpoR−/− MEFs. (D) Competitive binding studies using the 
EEL peptide in A2780-shEpoR or -shEphB4 cells. (E) Proximity ligation assay using 
Cos-1EpoR, Cos-1EphB4, and mutated EphB4 cells. Scale bar represents 50 μm. (F) Bar 
graph represents the quantification of ligation assay. (G) Competitive binding studies using 
soluble EphB4, EpoR or EphrinB2 in A2780-shEpoR cells. CPM, counts per minute. Mean 
± SEM values are shown. (n=3). (See also Figure S2 and Table S1-S2).
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Figure 3. Epo binding to EphB4 activates the Src-STAT pathway
(A) Activation of EphB4 by rhEpo in A2780-parental cells. (B) Evaluation of pJak-2, 
pSTAT5, and pSTAT3 levels (ELISA and Western blot) following rhEpo treatment in 
A2780, -shEpoR, and -shEphB4 cells. (C) Evaluation of pSTAT3 levels following rhEpo 
treatment in EpoR−/− MEFs. (D) Effect of rhEpo on EphB4 binding to Jak-2 and Src in 
A2780-EpoR cells. (E) Effect of Src inhibitor (PP2, 10μM; inactive counterpart, PP3) or Src 
siRNA on pSTAT3 levels following treatment with rhEpo in A2780-shEpoR cells, (RFUs - 
relative fluorescence units), n=3. (F) Effect of rhEpo on STAT3 binding to a oligonucleotide 
containing consensus STAT3 binding site in A2780-shEpoR and -shEphB4 cells. Dose of 
rhEpo used for these experiments was 50 IU/mL. Mean ± SEM values are shown. *p < 0.05; 
***p <0.001. (See also Figure S3).
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Figure 4. An essential role of EphB4 in rhEpo-mediated effects on cancer cells
(A) Effect of rhEpo on proliferation at indicated dosage. (B) Proliferation, (C) migration, 
and invasion of A2780, -shEpoR, and -shEphB4 cells after rhEpo treatment. (D) Effect of 
STAT3 silencing on migration and invasion in A2780-shEpoR cells. Mean ± SEM values 
are shown. *p < 0.05; **p < 0.01; ***p <0.001; ****p <0.0001. n=3. (See also Figure S4).
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Figure 5. EphB4 plays a key role in Epo-induced tumor growth in vivo
(A) Effect of rhEpo (50 IU given 3x/week i.p; n=10) on tumor growth (aggregate tumor 
weight after 3-5 weeks of rhEpo treatment) in orthotopic ovarian cancer models in vivo. (B) 
Effect of EphB4 and EpoR silencing on SKOV3ip1 and A2780 tumor growth in vivo with or 
without rhEpo treatment (n=10). Effect of EphB4 or EpoR silencing on the MDA-231 tumor 
growth in vivo with or without rhEpo treatment (n=10). (D) Effect of ectopically expressed 
EphB4 or EphB4 mutant on RMG2 tumor growth in vivo with or without rhEpo treatment 
(n=10). (E) Effect of rhEpo (50 IU given 3x/week i.p; n=10) on ID8-VEGF tumor growth 
(aggregate tumor weight after 3-5 weeks of rhEpo treatment; 1×106 ID8-VEGF murine 
ovarian cancer cells were injected into EphrinB2−/− mice). Mean ± SEM values are shown. 
**p < 0.01; ***p <0.001. (See also Figure S5).
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Figure 6. Clinical relevance of EphB4 and EpoR expression and ESA treatment in cancer 
patients
Representative immunohistochemical-peroxidase staining for (A) EphB4 and (B) EpoR 
expression in ovarian cancer, and (C) EphB4 and (D) EpoR expression in breast cancer 
samples. Kaplan-Meier curves of disease-specific mortality for ovarian (E-H) and breast (I-
J) cancer patients stratified by tumoral expression of (E) EphB4, (F) EpoR, or (G) both 
EphB4 and EpoR. (H) Evaluation of disease-specific survival duration of ovarian cancer 
patients based on ESA-treatment and EphB4 expression; (I) Disease-specific survival 
analysis of breast cancer patients stratified by ESA treatment; (J) Disease-specific survival 
of breast cancer patients based on ESA treatment and EphB4 expression. Scale bar 
represents 50 μm. (See also Figure S6 and Table S3-S7).
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Proposed model of Epo mediated EphB4 signaling in cancer cells.
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